Revisiting X-linked agammaglobulinemia

Area of Science:

• Immunology
• Genetics
• Infectious Diseases

Background:

• X-linked agammaglobulinemia (XLA) is a well-established inborn error of immunity (IEI) with an incidence of 1:100,000–1:200,000.
• Characterized by recurrent bacterial infections, hypo/agammaglobulinemia, and B-cell deficiency, its pathogenesis is understood, but several aspects remain unclear.

Purpose of the Study:

• To review and discuss unresolved issues in XLA.
• To highlight areas for future research and potential therapeutic advancements.

Main Methods:

• Literature review of existing studies on XLA.
• Discussion of current understanding and emerging challenges in XLA management.

Main Results:

• Identified unresolved issues include noncoding BTK variants, contiguous deletion syndrome, Helicobacter infection, neurodegeneration, renal involvement, and malignancies.
• Current primary treatment, immunoglobulin replacement therapy, has not changed.
• Allogeneic hematopoietic cell transplantation shows promise but requires further investigation.

Conclusions:

• Resolving these outstanding issues in XLA is a priority due to its prevalence among IEIs.
• Future research should focus on understanding and addressing these complex aspects of XLA.
• Exploring novel therapeutic strategies, including stem cell transplantation, may improve patient outcomes.